Company: MBIO
Filing Date: 2025-02-27
Form Type: 8-K
Source: 0001104659-25-018299
Chunk: 3

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-27
Form: 8-K
Item: Item 9.01
Chunk 3
---
Item
9.01 Financial Statements and Exhibits.

(d) Exhibits.

  Exhibit      Description                                                                                                                   
                                                                                                                                             
      No.                                                                                                                                    
      2.1      Bill of                                                                                                                       
               Sale and Surrender Agreement, dated January 31, 2025, by and between Mustang Bio, Inc. and AbbVie Bioresearch Center Inc.     
     10.1      First                                                                                                                         
               Amendment to Lease Agreement, dated February 7, 2025, by and between Mustang Bio, Inc. and WCS - 377 Plantation Street, Inc.  
     99.1      Press Release, dated February 27, 2025                                                                                        
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
      104      Cover Page Interactive Data File (formatted                                                                                   

SIGNATURES

Pursuant to the requirements of
the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.

  Mustang Bio, Inc.                                              
  (Registrant)                                                   
  By:                    /s/ Manuel Litchman, M. D.              
  Name:                  Manuel Litchman, M. D.                  
  Title:                 President, Chief Executive Officer and  
                         Interim Chief Financial Officer